Cantor Fitzgerald initiated coverage of Cybin (NYSE: CYBN), a drug development company in the psychedelics sector.
Analysts gave Cybin an overweight rating and a 12-month price target of $9. Cybin shares were $2.25 at the time of this writing.
This means that according to the financial firm Cybin stock could give a margin of 300% in just one year.
Cybin debuted on the NYSE earlier this month with a pipeline of novel psychedelic molecules for the treatment of …